These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 32336421)
1. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm. Xue T; Budde LE Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421 [TBL] [Abstract][Full Text] [Related]
2. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969 [TBL] [Abstract][Full Text] [Related]
3. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123. Zanotta S; Galati D; De Filippi R; Pinto A Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733 [TBL] [Abstract][Full Text] [Related]
4. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100 [TBL] [Abstract][Full Text] [Related]
5. Targeting CD123 in BPDCN: an emerging field. DiPippo AJ; Wilson NR; Pemmaraju N Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517 [TBL] [Abstract][Full Text] [Related]
6. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025 [TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126 [TBL] [Abstract][Full Text] [Related]
9. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Adimora IJ; Wilson NR; Pemmaraju N Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525 [TBL] [Abstract][Full Text] [Related]
11. CD123 as a Therapeutic Target Against Malignant Stem Cells. Sugita M; Guzman ML Hematol Oncol Clin North Am; 2020 Jun; 34(3):553-564. PubMed ID: 32336419 [TBL] [Abstract][Full Text] [Related]
12. CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Testa U; Pelosi E; Castelli G Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547472 [TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130 [TBL] [Abstract][Full Text] [Related]
14. CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm. Pelosi E; Castelli G; Testa U Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769040 [TBL] [Abstract][Full Text] [Related]
15. Blastic Plasmacytoid Dendritic Cell Neoplasm in Children. Li Y; Sun V; Sun W; Pawlowska A Hematol Oncol Clin North Am; 2020 Jun; 34(3):601-612. PubMed ID: 32336423 [TBL] [Abstract][Full Text] [Related]
16. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. Kharfan-Dabaja MA; Cherry M Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425 [TBL] [Abstract][Full Text] [Related]
17. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Jen WY; Konopleva M; Pemmaraju N Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053 [TBL] [Abstract][Full Text] [Related]
18. CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia. Shi M; Su RJ; Parmar KP; Chaudhry R; Sun K; Rao J; Chen M Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):195-204. PubMed ID: 31244444 [TBL] [Abstract][Full Text] [Related]
19. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia. Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444 [TBL] [Abstract][Full Text] [Related]
20. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]